Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0193 • ACR Convergence 2023
Social Vulnerability Associations with Mortality in a Lupus Cohort
Sean Carter¹, Dulaney Wilson¹, Samantha Minkin², David Dillon³, Baxter Murray¹, John Pearce¹ and Jim Oates¹, ¹Medical University of South Carolina, Charleston, SC, ²Vanderbilt University Medical Center, Nashville, TN, ³Rheumatology Associates of South Florida, Delray Beach, FL
Background/Purpose: The goal of this study is to identify characteristics of socially vulnerable environments associated with increased mortality in a South Carolina systemic lupus erythematosus…
Abstract Number: 0547 • ACR Convergence 2023
A Spatially-resolved Single Cell Resolution Atlas of Pediatric Lupus Nephritis Uncovers Complex Interactions Between Stromal and Infiltrating Immune Cells
Shaun Jackson¹, Nicholas Hasle², Elizabeth Nguyen³, Robyn Reed² and Patrick Danaher⁴, ¹Seattle Children's Research Institute / University of Washington, Seattle, WA, ²Seattle Children's Hospital/University of Washington, Seattle, WA, ³Seattle Children's Research Institute, Seattle, WA, ⁴Nanostring, Inc., Seattle, WA
Background/Purpose: The molecular and cellular heterogeneity of human Lupus Nephritis (LN) at the kidney tissue level makes it challenging to identify key disease drivers and…
Abstract Number: 0564 • ACR Convergence 2023
Risk Factors for Immune Thrombocytopenia in Systemic Lupus Erythematosus and Generation of a Predictive Model to Assess Its Risk of Development
Irene Carrión-Barberà¹, Jesús Cornudella Lema², Sergio Vázquez Montes de Oca³, Francesc García Pallarols¹, Jordi Monfort¹, Blanca Sánchez-González¹ and TAREK CARLOS SALMAN MONTE⁴, ¹Hospital del Mar, Barcelona, Spain, ²Faculty of Medicine, Pompeu Fabra University, Barcelona, Spain and Faculty of Medicine, Autonomous University of Barcelona, Barcelona, Spain, ³Biomedical Informatics Research Group, IMIM, Barcelona, Spain, ⁴Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with a wide variety of manifestations including immune thrombocytopenia (ITP), which has been described in 7-40%…
Abstract Number: 0582 • ACR Convergence 2023
Evaluation of Anifrolumab Treatment Responses by the Short Form 36 Health Survey Version 2 in SLE: A Post Hoc Analysis of the Placebo-Controlled Phase 3 Long-Term Extension Trial
Vibeke Strand¹, Kenneth Kalunian², Barnabas Desta³, Caroline Seo⁴, Gabriel Abreu⁵, Raj Tummala³, Catharina Lindholm⁵ and Hussein Al-Mossawi⁶, ¹Stanford University, Palo Alto, CA, ²University of California San Diego, La Jolla, CA, ³BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁴BioPharmaceuticals Medical Evidence, AstraZeneca, Gaithersburg, MD, ⁵BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ⁶BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom
Background/Purpose: SLE is a chronic disease that progressively reduces patients’ health-related quality of life.1 In a post hoc analysis of the TULIP trials, patients with…
Abstract Number: 0599 • ACR Convergence 2023
Targeted Inhibition of Cathepsins Limits the Intracellular Complement Activation in Lupus Nephritis Podocytes
Ana Kunzler¹, Meenakshi Jha¹, Masataka Umeda², Rhea Bhargava², Maria Tsokos¹, George Tsokos² and Abhigyan Satyam², ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease that leads to damage to several tissues and organs. Inflammation of the kidney is one…
Abstract Number: 0783 • ACR Convergence 2023
Tolerability of CAR T Cell Therapy in Autoimmune Disease
Jule Taubmann¹, Fabian Müller², Michael Aigner³, Ioanna Minopoulou⁴, Johannes Knitza⁵, Dagmar Werner⁶, Christina Bergmann⁷, Gerhard Kroenke⁸, Andreas Mackensen³ and Georg Schett⁶, ¹Department of Internal Medicine 3, Rheumatology and Immunology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ²Friedrich Alexander Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, ³Department of Internal Medicine 5, Hematology and Oncology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ⁴Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg & Universitätsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology / Deutsches Zentrum Immuntherapie, Erlangen, Germany, ⁵Department of Internal Medicine 3 Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, ⁶FAU Erlangen-Nürnberg, Erlangen, Germany, ⁷Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ⁸Charite Berlin, Berlin, Germany
Background/Purpose: We have previously shown that CD19 CAR T cell therapy can lead to improvement of severe forms of B cell mediated autoimmune disease including…
Abstract Number: 0891 • ACR Convergence 2023
Selective and Potent Inhibition of Cyclic GMP-AMP Synthase (cGAS) Fully Normalizes Autoinflammation Across Tissues in a Trex1-/- Mouse Model for Type I Interferonopathies
Arnaud Bourin¹, Zuzana Hořejší², Isabelle Cambré¹, Juraj Dobiaš², Mikhail Klychnikov², Radek Liboska², Maroš Smolíček², Zdeněk Vavřina², Wanda Haeck¹, Hugo Klaassen¹, Marnik Nijs¹, Kristine Metzger¹, Sandro Boland¹, Dries De Clercq¹, Sara Allasia¹, Gunter Carlens¹, Patrick Chaltin³, Arnaud Marchand¹, Ondřej Páv², Matthias Versele¹ and Gabriel Birkuš², ¹Centre for Drug Design and Discovery (CD3) - Cistim, Leuven, Belgium, ²Institute of Organic Chemistry and Biochemistry, Prague, Czech Republic, ³Centre for Drug Design and Discovery (CD3) - KU Leuven, Leuven, Belgium
Background/Purpose: The cGAS enzyme is a sensor of cytosolic double-strand (ds) DNA. It serves to detect viruses and elicits an acute, transient cGAMP-STING mediated type…
Abstract Number: 0912 • ACR Convergence 2023
Inadequate Screening for Antiphospholipid Syndrome with Antiphospholipid Antibodies in Patients with Systemic Lupus Erythematosus
tooba Munawar¹, Mahnoor Sherazi² and Andras Perl³, ¹Upstate University Hospital, Jamesville, NY, ²Upstate University Hospital, Syracuse, NY, ³SUNY, Syracuse, NY
Background/Purpose: Antiphospholipid Syndrome (APS) is classified into primary and secondary; the latter being associated with connective tissue disease. Systemic lupus erythematosus (SLE) is the most…
Abstract Number: 0932 • ACR Convergence 2023
The Landscape of Immune Cells in Systematic Lupus Erythematosus Patients with Epstein-Barr Virus Infection by Single-cell Sequencing
Lingzhen Hu¹, Jianxin Tu¹, Jiajun Gui², Mengyuan Fang², Xiaowei Chen¹ and Li Sun¹, ¹The First Affliated Hospital of Wenzhou Medical University, Wenzhou, China, ²The First Clinical College, Wenzhou Medical University, Wenzhou, China
Background/Purpose: This study aimed to analyze the immune cell profiles, especially B cells and B-cell receptor (BCR) of systematic lupus erythematosus (SLE) patients with or…
Abstract Number: 1229 • ACR Convergence 2023
Longitudinal Assessment of Self-reported Executive Function in Youth with Childhood-Onset Lupus
Tala El Tal¹, justine ledochowski², Sarah Mossad³, Victoria Lishak³, Ibrahim Mohamed⁴, Joanna Law³, Lawrence Ng³, Paris Moaf³, Asha Jeyanathan³, Adrienne Davis³, Linda Hiraki³, Deborah Levy³, Zahi Touma⁵, Natoshia Cunningham⁶, Ashley Danguecan³ and Andrea Knight³, ¹Division of Rheumatology, The Hospital for Sick Children, andDivision of Rheumatology, Children’s Hospital of Eastern Ontario, Ottawa, ON, Canada, ²Department of Psychology, The Hospital for Sick Children, Toronto, ON, Canada, ³The Hospital for Sick Children, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Brampton, ON, Canada, ⁵University of Toronto, Toronto, ON, Canada, ⁶Michigan State University, Grand Rapids, MI
Background/Purpose: Cognitive dysfunction (including executive dysfunction) affects up to 60% of youth with childhood-onset systemic lupus erythematosus (cSLE), with potential adverse effects on health-related quality…
Abstract Number: 1357 • ACR Convergence 2023
Systemic Lupus Erythematosus and Assisted Reproductive Technology: A Case Series and Systematic Literature Review
Erinn Coe¹, Emily Petrinec¹ and Omer Pamuk², ¹Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH, ²Division of Rheumatology, Case Western Reserve University/University Hospitals, Cleveland, OH
Background/Purpose: Systemic lupus erythematosus (SLE) is one of the most common autoimmune diseases in women of childbearing age and female sex hormones are known to…
Abstract Number: 1454 • ACR Convergence 2023
Neuropsychiatric Systemic Lupus Erythematosus in Children: A Scoping Review
Alexandra Theisen¹, Ekemini Ogbu², Emily Beil³, Onengiya Harry⁴, Simone Appenzeller⁵, Ryan Kammeyer⁶, Hanne Van der Heijen⁷, Andrea Knight⁸, Hannah Craven⁹ and Martha Rodriguez¹⁰, ¹Saint Louis University School of Medicine, SSM Health Cardinal Glennon Children's Hospital, St. Louis, MO, ²Cincinnati Children's Hospital Medical Center, University of Cincinnati School of Medicine, Johns Hopkins University, Cincinnati, OH, ³Baylor College of Medicine / Texas Children's Hospital, Houston, TX, ⁴Brenner Children's Hospital - Wake Forest Baptist Health, Winston-Salem, NC, ⁵UNICAMP, Campinas, Brazil, ⁶University of Colorado School of Medicine, Children's Hospital Colorado, Denver, CO, ⁷Boston Children's Hospital, Harvard Medical School, Boston, MA, ⁸The Hospital for Sick Children, Toronto, ON, Canada, ⁹Ruth Lilly Medical Library, Indiana University School of Medicine, Indianapolis, IN, ¹⁰Indiana University School of Medicine, Riley Hospital for Children, Indianapolis, IN
Background/Purpose: Neuropsychiatric systemic lupus erythematosus (NPSLE) remains a challenging entity to diagnose and treat. The clinical heterogeneity of NPSLE coupled with the difficulty with attribution…
Abstract Number: 1471 • ACR Convergence 2023
A Comparative Study of Lupus Nephritis Class II and IgA Nephropathy: Renal Disease Other Than Lupus Nephritis in Systemic Lupus Erythematosus Patients
Eun song Kang¹ and Seokchan Hong², ¹Korea University Ansan Hospital, Seoul, South Korea, ²Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
Background/Purpose: Lupus nephritis (LN) is one of major organ involvement of SLE and renal biopsy is commonly performed in SLE patients suspected of having LN…
Abstract Number: 1489 • ACR Convergence 2023
Treatment with Upadacitinib in Patients with Systemic Lupus Erythematosus Results in the Inhibition of B-Cell–related Biomarkers: Analysis of the M19-130 (SLEek) Phase 2 Study
Marie-Claude Gaudreau¹, James Fann¹, Alan Friedman¹, Thierry Sornasse¹ and Joan Merrill², ¹AbbVie, Inc., North Chicago, IL, ²Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: B-cell hyperactivity (1) is a hallmark of the disordered immunity of SLE, arising in the context of a complex array of innate and adaptive…
Abstract Number: 1507 • ACR Convergence 2023
Pharmacodynamic Changes in SLE Relevant Gene Expression Induced by Deucravacitinib in Patients Enrolled in the Phase 2 PAISLEY Trial
Chun Wu¹, Cristina Arriens², J. Michelle Kahlenberg³, Yanhua Hu¹, Coburn Hobar¹, Adrian Coles⁴ and Ian M. Catlett⁵, ¹Bristol Myers Squibb, Princeton, NJ, ²Oklahoma Medical Research Foundation and University of Oklahoma Health Sciences Center, Department of Arthritis & Clinical Immunology, Oklahoma City, OK, ³University of Michigan, Ann Arbor, MI, ⁴Bristol Myers Squibb, Lawrenceville, NJ, ⁵Bristol Myers Squibb, Pennington, NJ
Background/Purpose: Deucravacitinib (DEUC) is a first-in-class, oral, selective, allosteric inhibitor of TYK2. TYK2 is required for signal transduction downstream of cytokines implicated in SLE pathophysiology,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].